Search by therapeutic area for drugs approved by the Food and Drug Administration (FDA) for sale in the
United States. Click on an area below to view the complete list of drugs in that category or
review descriptions for our therapeutic
area list to assist you in your search.
FDA Approved Drugs for Hematology
Drugs Approved in 2013
Kcentra (Prothrombin Complex Concentrate); CSL Behring;
For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency, Approved May 2013
Nymalize (nimodipine); Arbor Pharmaceuticals;
For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013
Pomalyst (pomalidomide); Celgene;
For the treatment of relapsed and refractory multiple myeloma, Approved February 2013
Ravicti (glycerol phenylbutyrate); Hyperion Therapeutics;
For the treatment of pediatrics and adults with urea cycle disorders, Approved February 2013
Drugs Approved in 2012
Bosulif (bosutinib); Pfizer;
For the treatment of Ph+ chronic myelogenous leukemia, Approved September 2012
Elelyso (taliglucerase alfa); Pfizer;
For the treatment of Gaucher disease, Approved May 2012
Iclusig (ponatinib); Ariad Pharmaceuticals;
For the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, Approved December 2012
Kyprolis (carfilzomib); Onyx Pharmaceuticals;
For the treatment of multiple myeloma, Approved July 2012
Marqibo (vinCRIStine sulfate LIPOSOME injection); Talon Therapeutics;
For the treatment of Ph- acute lymphoblastic leukemia, Approved August 2012
Neutroval (tbo-filgrastim); Teva Pharmaceutical;
For the reduction in the duration of severe chemotherapy-induced neutropenia, Approved August 2012
Omontys (peginesatide); Affymax;
For the treatment of anemia due to chronic kidney disease, Approved March 2012
Synribo (omacetaxine mepesuccinate); Teva Pharmaceutical;
For the treatment of chronic or accelerated phase chronic myeloid leukemia, Approved October 2012
Drugs Approved in 2011
Adcretris (brentuximab vedotin); Seattle Genetics;
For the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, Approved August 2011
Erwinaze (asparaginase Erwinia chrysanthemi); Eusa Pharma;
For the treatment of acute lymphoblastic leukemia, Approved November of 2011
Ferriprox (deferiprone); Apotex;
For the treatment of transfusional iron overload due to thalassemia, Approved October 2011
Jakafi (ruxolitinib); Incyte;
For the treatment of myelofibrosis, Approved November 2011
Soliris (eculizumab); Alexion;
For the treatment of atypical hemolytic uremic syndrome, Approved September 2011
Xarelto (rivaroxaban); Bayer;
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011
Drugs Approved in 2010
Vpriv (velaglucerase alfa for injection); Shire Pharmaceuticals;
For the treatment of type 1 Gaucher disease, Approved March 2010
Drugs Approved in 2009
Arzerra (ofatumumab); GlaxoSmithKline;
For the treatment of chronic lymphocytic leukemia, Approved October 2009
Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics;
For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009
Efient (prasugrel); Eli Lilly;
for the prevention of thrombotic cardiovascular complications in acute coronary syndromes, Approved July 2009
Elitek (rasburicase); sanofi-aventis;
For the management of plasma uric acid levels in adults with malignancies, Approved October 2009
Feraheme (ferumoxytol); AMAG;
For the treatment of iron deficiency anemia associated with chronic kidney disease, Approved June 2009
Folotyn (pralatrexate injection); Allos Therapeutics;
For the treatment of peripheral T-cell lymphoma, Approved September 2009
Istodax (romidepsin); Gloucester Pharmaceuticals;
For the treatment of cutaneous T-cell lymphoma, Approved November 2009
Samsca (tolvaptan); Otsuka;
For the treatment of hyponatremia, Approved May of 2009
Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human); Octapharma;
For the treatment of von Willebrand disease, Approved December of 2009
Drugs Approved in 2008
Mozobil (plerixafor injection); Genzyme;
For the treatment of non-Hodgkin’s lymphoma and multiple myeloma, Approved December 2008
Nplate (romiplostim); Amgen;
For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, Approved August 2008
Promacta (eltrombopag); GlaxoSmithKline;
For the treatment of thrombocytopenia, Approved November 2008
Drugs Approved in 2007
Kuvan (sapropterin dihydrochloride); BioMarin Pharmaceuticals;
For the treatment of hyperphenylalaninemia due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria, Approved December 2007
Mircera (methoxy polyethylene glycol-epoetin beta); Roche;
For the treatment of anemia associated with chronic renal failure, Approved November 2007
Soliris (eculizumab); Alexion;
For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007
Drugs Approved in 2006
Dacogen (decitabine); MGI Pharma;
For the treatment of both treatment-naïve and -experienced Myelodysplastic Syndromes, Approved May 2006
Drugs Approved in 2005
Revlimid (lenalidomide); Celgene;
For the treatment of low- and intermediate-1-risk myelodysplastic syndromes, Approved December 2005
Drugs Approved in 2004
Vidaza (azacitidine); Pharmion Corporation;
For the treatment of several myelodysplastic syndrome subtypes including refractory and chronic myelomonocytic leukemias, Approved May 2004
Drugs Approved in 2003
Bexxar; Corixa;
For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse, Approved June 2003
Levitra (vardenafil); Bayer, GlaxoSmithKline;
For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003
Reyataz (atazanavir sulfate); Bristol-Myers Squibb;
For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003
Zemaira (alpha1-proteinase inhibitor); Aventis Behring;
For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema, Approved July 2003
Drugs Approved in 2002
Neulasta; Amgen;
Treatment to decrease the chance of infection by febrile neutropenia in patients receiving chemotherapy, Approved January 2002
Drugs Approved in 2001
Arixtra; Organon, Sanofi-Synthelabo;
Injectable solution for the prevention of deep vein thrombosis, Approved December 2001
Drugs Approved in 2000
Argatroban Injection; Texas Biotechnology Corporation, SmithKline Beecham;
Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia., Approved June 2000
Innohep (tinzaparin sodium) injectable; DuPont Merck Pharmaceutical Company;
For the treatment of acute symptomatic deep vein thrombosis, Approved July 2000
Kogenate FS (Antihemophilic Factor Recombinant); Bayer;
For the treatment of hemophilia A, Approved June 2000
Renagel (sevelamer hydrochloride); Genzyme;
For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved July of 2000
Venofer (iron sucrose injection); Luitpold Pharmaceuticals;
For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis, Approved November 2000
Drugs Approved in 1999
Aggrenox; Boehringer Ingelheim;
Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999
Busulflex; Orphan Medical;
For use in combination for the treatment of leukemia, Approved February 1999
Ferrlecit; R&D Laboratories;
For the treatment of iron deficiency anemia., Approved February 1999
Fragmin; Pharmacia & Upjohn;
Treatment of prophylaxis of deep vein thrombosis (DVT), Approved March 1999
Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer;
Treatment for acute deep vein thrombosis, Approved January 1999
Drugs Approved in 1998
Actonel; Procter & Gamble, Hoechst Marion Roussel;
Treatment for Paget's Disease, Approved April 1998
Droxia; Bristol-Myers Squibb;
Treatment for sickle-cell anemia, Approved March 1998
Glucagon; Eli Lilly;
Treatment for severe Hypoglycemia, Approved September 1998
Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer;
Treatment for prevention of blood clots following hip-replacement surgery, Approved February 1998
Neupogen; Amgen;
Treatment for slow white blood cell recovery following chemotherapy, Approval April 1998
Refludan; Hoechst Marion Roussel;
Treatment of heparin-induced thrombocytopenia type II, Approved March 1998
Drugs Approved in 1997
Agrylin (anagrelide HCL); Roberts Pharmaceutical;
Treatment for thrombocythemia, Approved March 1997
BeneFIX (coagulation Factor IX (recombinant)); Genetics Institute;
Treatment for hemophilia B, Approved February 1997
Glyburide Tablets; Roche;
Treatment for blood-glucose lowering, Approved December 1997
Glyburide Tablets; Mova Pharmaceutical;
Generic version of Glynase PresTab, Approved December 1997
Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer;
Treatment for deep vein thrombosis, Approved May 1997
Neumega; Genetics Institute;
Treatment for thrombocytopenia, Approved November 1997
Rituxan; Biogen IDEC, Genentech;
Treatment for non-hodgkin's lymphoma, Approved November 1997
Drugs Approved in 1996
AlphaNine SD Coagulation Factor IX (Human); Alpha Therapeutic Corporation;
Treatment for the prevention and control of bleeding in subjects with hemophilia, Approved July 1996
Gastrocrom Oral Concentrate (cromolyn sodium); Rhone Poulenc Rorer;
Treatment for mastocytosis, Approved April 1996
Leukine (sargramostim); Immunex;
Treatment for the replenishment of white blood cells, Approved November 1996
Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals;
Treatment for vitamin B-12 deficiency, Approved November 1996
Pravachol (pravastatin sodium); Bristol-Myers Squibb;
Treatment for cholesterol-lowering, Approved July 1996
Visipaque (iodixanol); Nycomed;
Diagnostic contrast agent, Approved April 1996
